Literature DB >> 23901022

Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Jorge Monge1, Esteban Braggio, Stephen M Ansell.   

Abstract

Waldenström's macroglobulinemia (WM) is an indolent but incurable B-cell malignancy. Over the last decade, advances in the molecular field brought about by the use of high-throughput genomic analyses-including array-based comparative genomic hybridization and massively parallel genome sequencing-have considerably improved our understanding of the genetic basis of WM. Its pathogenesis, however, remains fragmented. Important steps have been made in elucidating the underlying aberrations and deregulated mechanisms of the disease, and thereby providing invaluable information for identifying biomarkers for disease diagnosis, risk stratification, and therapeutic approaches. We review the genetic basis of the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23901022      PMCID: PMC3807757          DOI: 10.1007/s11912-013-0331-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  73 in total

1.  Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.

Authors:  R G Owen; S L Barrans; S J Richards; S J O'Connor; J A Child; L A Parapia; G J Morgan; A S Jack
Journal:  Am J Clin Pathol       Date:  2001-09       Impact factor: 2.493

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  VWF, WM, and angiogenesis: is there a link?

Authors:  Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

4.  Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells.

Authors:  Ruth M de Tute; Andy C Rawstron; Roger G Owen
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-22

Review 5.  Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Morie A Gertz
Journal:  Am J Hematol       Date:  2012-05       Impact factor: 10.047

6.  Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Alexandra Wikowicz; Evangelos Terpos; Marita Ziepert; Diana Nikolaus; Yin Yang; Natalie Fadle; Evi Regitz; Meletios A Dimopoulos; Steven P Treon; Zachary R Hunter; Michael Pfreundschuh
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

7.  microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Xiaoying Jia; Abdel Kareem Azab; Patricia Maiso; Hai T Ngo; Feda Azab; Judith Runnels; Phong Quang; Irene M Ghobrial
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

8.  Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.

Authors:  Irene M Ghobrial; Rafael Fonseca; Morie A Gertz; Matthew F Plevak; Dirk R Larson; Terry M Therneau; Robert C Wolf; Randi J Hoffmann; John A Lust; Thomas E Witzig; Martha Q Lacy; Angela Dispenzieri; S Vincent Rajkumar; Stephen R Zeldenrust; Philip R Greipp; Robert A Kyle
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

9.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

10.  Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

Authors:  Steven P Treon; Christina Tripsas; Christina Hanzis; Leukothea Ioakimidis; Christopher J Patterson; Robert J Manning; Patricia Sheehy; Barry Turnbull; Zachary R Hunter
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-17
View more
  4 in total

Review 1.  [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].

Authors:  A Grunenberg; C Buske
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

2.  Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Authors:  Shahrzad Jalali; Tammy Price-Troska; Jonas Paludo; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Stephen M Ansell
Journal:  Blood Adv       Date:  2018-08-14

3.  Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.

Authors:  Naohiro Sekiguchi; Junko Nomoto; Akihisa Nagata; Masahiro Kiyota; Ichiro Fukuda; Kazuaki Yamada; Naoki Takezako; Yukio Kobayashi
Journal:  Biomed Res Int       Date:  2018-10-04       Impact factor: 3.411

Review 4.  Multilocus Inherited Neoplasia Allele Syndrome (MINAS): an update.

Authors:  Anthony McGuigan; James Whitworth; Avgi Andreou; Timothy Hearn; Marc Tischkowitz; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2022-01-04       Impact factor: 4.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.